One of the recurring concerns with the IDSA AMR Guidance is the heavy reliance on in vitro susceptibility data, PK/PD principles, and animal models, while often giving less weight to higher levels of clinical evidence, including randomized controlled trials and well-conducted observational studies. Preclinical data are invaluable for hypothesis generation, but when robust clinical outcome data are available, they should take precedence. Guideline development also requires intellectual humility—recognizing uncertainty, acknowledging the limitations of the available evidence, and being willing to revise recommendations when higher-quality clinical data emerge. That is how evidence-based medicine advances and how patient care improves. @BradSpellberg @DrToddLee #idxposts